Home › Phases › Phase 2

Phase 2 (162 companies)

Companies with at least one active program at Phase 2.

Ticker Company Therapeutic areas Phase 2 programs Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 1 Phase 3 $608M 5
ABVX Abivax Immunology 1 Phase 3 $7.19B 2
ACIU AC Immune Neurology Rare 4 Phase 3 $210M 11
QUIT Achieve Life Sciences — 1 NDA Submitted $673M 2
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 2 Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 4 Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology 1 Phase 2 $15.2M 4
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 $16.6M 4
ADAG Adagene Oncology 3 Phase 2 $99.4M 10
ADCT ADC Therapeutics Oncology 3 Approved $172M 5
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 1 Approved $1.79B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 4 Approved $111M 10
ALLO Allogene Therapeutics ImmunologyOncology Rare 1 Phase 2 $256M 10
DRTS Alpha Tau Medical Oncology 4 Phase 2 $1.12B 6
ATHE Alterity Therapeutics Neurology Rare 1 Phase 2 $35.7M 2
ALT Altimmune GI/HepatologyMetabolic+1 2 Phase 3 $298M 3
ANRO Alto Neuroscience Neurology 6 Phase 2 $999M 6
ALMS Alumis DermatologyImmunology+1 1 Phase 3 $628M 5
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 1 Phase 2 $161M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 1 Approved $1.36B 9
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 $662M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 — 9
ARVN Arvinas NeurologyOncology Rare 1 Approved $447M 10
ATAI Atai Beckley Neurology 3 Phase 2 $2.73B 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 2 Approved $290M 12
AXSM Axsome Therapeutics Neurology Rare 1 Approved $7.15B 15
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.14B 6
BCAX Bicara Therapeutics Oncology 1 Phase 2 $637M 4
BCYC Bicycle Therapeutics Oncology 2 Phase 2 $224M 4
BIOA BioAge Labs CardiovascularOphthalmology 2 Phase 2 $234M 2
BMEA Biomea Fusion MetabolicOncology 2 Phase 2 $35.5M 4
BDTX Black Diamond Therapeutics Oncology 2 Phase 2 $82.8M 4
CCCC C4 Therapeutics Oncology 1 Phase 2 $332M 2
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 $124M 4
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 1 Phase 3 $187M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 1 Phase 3 $2.20B 6
CLRB Cellectar Biosciences Oncology 4 Phase 2 $9.2M 7
CRVO CervoMed Neurology Rare 3 Phase 2 $22.7M 4
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 2 Phase 2 $13.2M 4
CLNN Clene Neurology Rare 2 NDA Submitted $46.4M 5
CLYM Climb Bio HematologyImmunology+1 Rare 2 Phase 2 $574M 8
CGTX Cognition Therapeutics Neurology 2 Phase 2 $59.9M 2
CHRS Coherus Oncology Oncology 1 Approved $74.0M 5
CMPS COMPASS Pathways Neurology 2 NDA Submitted $1.13B 3
CMPX Compass Therapeutics Oncology 2 Phase 2 $109M 15
CGEN Compugen Oncology 1 Phase 3 $191M 7
CNTB Connect Biopharma Respiratory 4 Phase 2 $37.3M 4
CTNM Contineum Therapeutics NeurologyRespiratory Rare 3 Phase 2 $375M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 3 Phase 3 $858M 7
COYA Coya Therapeutics Neurology Rare 1 Phase 2 $70.8M 6
CBIO Crescent Biopharma Oncology 1 Phase 2 $507M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 1 Approved — 6
CUE Cue Biopharma ImmunologyOncology 1 Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $602M 10
CYDY CytoDyn NeurologyOncology 2 Phase 2 $367M 3
DFTX Definium Therapeutics Neurology 1 Phase 3 $4.02B 4
IRON Disc Medicine GI/HepatologyHematology+2 Rare 3 Phase 3 $3.49B 9
EWTX Edgewise Therapeutics Cardiovascular 3 Phase 2 $4.60B 3
EIKN Eikon Therapeutics Oncology 2 Phase 2 $279M 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 2 Phase 2 $167M 3
ELTX Elicio Therapeutics Oncology 1 Phase 2 $40.5M 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 1 Phase 2 $48.0M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 3 Approved $253M 8
ENTX Entera Bio GI/HepatologyMetabolic Rare 2 Phase 2 $522M 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.84B 17
EVMN Evommune DermatologyImmunology+1 3 Phase 2 $290M 6
EXEL Exelixis CardiovascularOncology 3 Approved $16.7B 23
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $124M 10
FBRX Forte Biosciences DermatologyGI/Hepatology 1 Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+4 Rare 2 Approved $61.4M 16
GNLX Genelux Oncology 1 Phase 3 $96.1M 3
GERN Geron Oncology 1 Approved $644M 3
GHRS GH Research NeurologyWomen's Health 3 Phase 2 $1.25B 4
GOSS Gossamer Bio Cardiovascular Rare 2 NDA Submitted $67.5M 4
HRMY Harmony Biosciences MetabolicNeurology Rare 1 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 1 Approved $1.11B 15
HELP Helus Pharma Neurology 2 Phase 3 $575M 3
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $116M 4
IBRX ImmunityBio Infectious DiseaseOncology 7 Approved $6.66B 17
IMVT Immunovant ImmunologyNeurology Rare 3 Phase 3 $6.87B 4
IXHL Incannex Healthcare NeurologyRespiratory 2 Phase 2 $21.8M 2
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.10B 6
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 1 Approved $4.49B 29
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 $1.07B 4
KAPA Kairos Pharma Oncology 1 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 6 Phase 2 $60.7M 13
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $222M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare 2 Phase 3 $4.1M 4
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 2 Phase 2 $10.4B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 2 NDA Submitted $297M 6
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.30B 3
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 1 Phase 2 $236M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $207M 13
LGVN Longeveron CardiovascularNeurology Rare 2 Phase 2 $7.1M 3
MPLT MapLight Therapeutics Neurology 3 Phase 2 $365M 3
MAZE Maze Therapeutics MetabolicRenal Rare 3 Phase 2 $1.80B 4
MDNAF Medicenna Therapeutics Oncology 1 Phase 2 $14.8M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 2 Phase 3 $827M 16
MLYS Mineralys Therapeutics CardiovascularRenal+1 2 NDA Submitted $1.28B 3
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $47.7M 8
MBRX Moleculin Biotech Oncology 3 Phase 2 $7.3M 9
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 2 Phase 2 $775M 7
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 2 NDA Submitted $957M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 5 Phase 3 $1.23B 11
NRSN NeuroSense Therapeutics Neurology Rare 2 Phase 2 $2.9M 3
NAMS NewAmsterdam Pharma CardiovascularMetabolic+1 1 NDA Submitted $2.33B 6
NBP NovaBridge Biosciences OncologyOphthalmology 3 Phase 2 $95.4M 7
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 2 Phase 3 $1.56B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $660M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare 1 Phase 3 $257M 12
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $418M 5
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.04B 6
ONCY Oncolytics Biotech Oncology 2 Phase 2 $51.7M 4
IRD Opus Genetics Ophthalmology Rare 1 Approved $391M 12
ORKA Oruka Therapeutics DermatologyImmunology Rare 3 Phase 2 $6.53B 7
OVID Ovid Therapeutics Neurology Rare 1 Phase 2 $419M 4
PTN Palatin Technologies ImmunologyMetabolic+1 2 Phase 3 $9.5M 5
PALI Palisade Bio Immunology 1 Phase 2 $181M 3
PEPG PepGen Neurology Rare 1 Phase 2 $269M 1
PMVP PMV Pharmaceuticals Oncology 7 Phase 2 $92.2M 7
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $4.8M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 1 Approved $8.14B 12
TARA Protara Therapeutics DermatologyMetabolic+1 Rare 2 Phase 3 $143M 3
QTTB Q32 Bio Dermatology 1 Phase 2 $258M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 2 Phase 2 $236M 4
RAPP Rapport Therapeutics Neurology 1 Phase 3 $1.41B 6
RXRX Recursion Pharmaceuticals Oncology 1 Phase 2 $1.69B 6
RNTX Rein Therapeutics Respiratory Rare 1 Phase 2 $30.7M 1
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $3.64B 4
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 3 Phase 2 $321M 4
REPL Replimune Group Oncology 4 Approved $1.87B 5
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved $8.08B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved $236M 4
SABS SAB Biotherapeutics Metabolic 1 Phase 2 $266M 1
SGMT Sagimet Biosciences DermatologyMetabolic 1 Phase 3 $709M 3
SLS SELLAS Life Sciences Group Oncology 1 Phase 3 $3.90B 9
SION Sionna Therapeutics Respiratory Rare 1 Phase 2 $139M 5
SYRE Spyre Therapeutics DermatologyImmunology Rare 9 Phase 2 $8.91B 10
SMMT Summit Therapeutics Oncology 2 NDA Submitted $8.53B 6
TECX Tectonic Therapeutic Cardiovascular Rare 2 Phase 2 $401M 4
TLX Telix Pharmaceuticals Oncology 3 Approved $3.01B 25
TGTX Tg Therapeutics Neurology Rare 2 Approved $9.48B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 4 Phase 2 $83.2M 5
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved $4.91B 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 1 Phase 2 $261M 4
TYRA Tyra Biosciences MetabolicOncology Rare 3 Phase 2 $1.35B 5
UPB Upstream Bio Respiratory 3 Phase 2 $115M 3
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 2 Approved $230M 27
PCVX Vaxcyte Infectious Disease 1 Phase 3 $9.40B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 4 Approved $1.89B 6
VSTM Verastem Oncology 4 Approved $934M 5
VRCA Verrica Pharmaceuticals DermatologyOncology Rare 1 Approved $53.9M 4
VKTX Viking Therapeutics MetabolicNeurology Rare 4 Phase 3 $3.43B 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 3 Phase 3 $69.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $560M 5
XNCR Xencor ImmunologyNeurology+1 Rare 3 Approved $2.59B 28
XERS Xeris Biopharma MetabolicNeurology Rare 1 Approved $3.07B 4
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 2 NDA Submitted $1.88B 11
ZURA Zura Bio DermatologyImmunology Rare 2 Phase 2 $99.7M 4